NASA SBIR 2012 Solicitation

FORM B - PROPOSAL SUMMARY


PROPOSAL NUMBER: 12-1 H12.05-8845
SUBTOPIC TITLE: In-Flight Biological Sample Analysis
PROPOSAL TITLE: Low Gravity Drug Stability Analyzer

SMALL BUSINESS CONCERN (Firm Name, Mail Address, City/State/Zip, Phone)
Real-Time Analyzers, Inc.
362 Industrial Park Rd (#8)
Middletown, CT 06457 - 1548
(860) 635-9800

PRINCIPAL INVESTIGATOR/PROJECT MANAGER (Name, E-mail, Mail Address, City/State/Zip, Phone)
Hermes Huang
hermes@rta.biz
362 Industrial Park Rd (#8)
Middletown, CT 06457 - 1548
(860) 635-9800 Extension :233

CORPORATE/BUSINESS OFFICIAL (Name, E-mail, Mail Address, City/State/Zip, Phone)
Stuart Farquharson
stu@rta.biz
362 Industrial Park Rd (#8)
Middletown, CT 06457 - 1548
(860) 635-9800 Extension :230

Estimated Technology Readiness Level (TRL) at beginning and end of contract:
Begin: 3
End: 7

Technology Available (TAV) Subtopics
In-Flight Biological Sample Analysis is a Technology Available (TAV) subtopic that includes NASA Intellectual Property (IP). Do you plan to use the NASA IP under the award?
No

TECHNICAL ABSTRACT (Limit 2000 characters, approximately 200 words)
The overall goal of this proposed program (through Phase III) is to build a space-worthy Drug Stability Analyzer that can determine the extent of drug degradation. It will be able to monitor the drug active pharmaceutical ingredient (API) and its degradation product concentrations as a function of time, as well as determine if a drug is suitable for use (likely based on the presence of 90% or more of the original API concentration). This will be accomplished by designing and building a rugged, small, light weight, low power, easy to use analyzer with appropriate software, which can identify and quantify API and degradation products with little or no sample handling in 1 minute. Feasibility will be demonstrated during Phase I by successfully measuring acetaminophen, azithromycin, epinephrine, lidocaine, and their degradation products at percent level concentrations.

The overall goal of the Phase II program is to build a working prototype Drug Stability Analyzer that is suitable for space deployment (e.g. aboard the ISS) and capable of monitoring drug degradation. The ability of the analyzer to nondestructively quantify the amount of the API and the degradation products, would also allow assessing drug potency at the time of use to ensure crewmember safety. The Drug Stability Analyzer will be transitioned from a Technology Readiness Level 3 to a 7 (ground tested) from the beginning to the end of the program.

POTENTIAL NASA COMMERCIAL APPLICATIONS (Limit 1500 characters, approximately 150 words)
The proposed Drug Stability Analyzer is specifically being designed to monitor degradation of pharmaceutical drugs that are used by astronauts, so that drug types, formulations, and packaging can be improved, and supplies can be selected to match mission length. It will also have the capability of determining if a drug is suitable at the time of use (effective and safe).

POTENTIAL NON-NASA COMMERCIAL APPLICATIONS (Limit 1500 characters, approximately 150 words)
Successful development of the Drug Stability Analyzer will have great value to pharmacies worldwide. It will allow more accurate determination of whether a product on the shelf can be safely sold to customers, or whether it must be discarded, compared to a simple expiration date.

TECHNOLOGY TAXONOMY MAPPING (NASA's technology taxonomy has been developed by the SBIR-STTR program to disseminate awareness of proposed and awarded R/R&D in the agency. It is a listing of over 100 technologies, sorted into broad categories, of interest to NASA.)
Analytical Instruments (Solid, Liquid, Gas, Plasma, Energy; see also Sensors)
Health Monitoring & Sensing (see also Sensors)
Lifetime Testing
Medical


Form Generated on 03-28-13 15:21